Source:http://linkedlifedata.com/resource/pubmed/id/11025741
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-11-21
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0022-5347
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
164
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1666
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11025741-Adjuvants, Immunologic,
pubmed-meshheading:11025741-BCG Vaccine,
pubmed-meshheading:11025741-Carcinoma in Situ,
pubmed-meshheading:11025741-Cystectomy,
pubmed-meshheading:11025741-Doxorubicin,
pubmed-meshheading:11025741-Humans,
pubmed-meshheading:11025741-Urinary Bladder Neoplasms
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
|
| pubmed:publicationType |
Letter,
Comment
|